Biopharma & Life Sciences
Viatris Executive Compensation (FY25)
VTRS · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): May 15, 2026
237 figures on this page: 231 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Scott Smith was paid $15,273,331 in total compensation as Chief Executive Officer for fiscal 2025, and compared with the $14,759,379 reported for fiscal 2024, Smith's total was 3.5% higher. The disclosed chief executive pay ratio for fiscal 2025 is 327:1, against median employee compensation of $46,729. Shareholders supported the say-on-pay proposal with 96.9% of votes cast for or against in favor at the meeting held May 15, 2026 for fiscal 2025. Companies named in the disclosed peer group include Abbott Laboratories, Amgen Inc., Bausch Health Companies Inc., Baxter International Inc. and Biogen Inc., among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Scott Smith: $14,759,379 → $15,273,331 (3.5% higher)
Say-on-pay support: 95.6% → 96.9% (1.3 points higher)
CEO pay ratio: 304:1 → 327:1 (7.6% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Viatris' chief executive and what were they paid?
Scott Smith was paid $15,273,331 in total compensation as Chief Executive Officer for fiscal 2025. Compared with the $14,759,379 reported for fiscal 2024, Smith's total was 3.5% higher.
What was Viatris' say-on-pay result?
Shareholders supported the say-on-pay proposal with 96.9% of votes cast for or against in favor at the meeting held May 15, 2026 for fiscal 2025.
Which companies are in Viatris' peer group?
Companies named in the disclosed peer group include Abbott Laboratories, Amgen Inc., Bausch Health Companies Inc., Baxter International Inc. and Biogen Inc., among others.
What is Viatris' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 327:1, against median employee compensation of $46,729.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Smith Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Brian Roman Former Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Smith Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Doretta Mistras Chief Financial Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Corinne Le Goff Chief Commercial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Brian Roman Former Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Smith Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Corinne Le Goff Chief Commercial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Doretta Mistras Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Brian Roman Former Chief Legal Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Andrew Enrietti Chief Administrative and Transformation Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew Enrietti | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew Enrietti | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew Enrietti | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Brian Roman | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Brian Roman | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Corinne Le Goff | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Corinne Le Goff | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Doretta Mistras | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Doretta Mistras | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Scott A. Smith | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Scott A. Smith | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Scott Smith | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Doretta Mistras | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Andrew Enrietti | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Brian Roman | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Corinne Goff | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Melina Higgins Board chair | ◇ | ◇ | — | — | — | ◇ | ◇ |
Mark Parrish | ◇ | ◇ | — | — | — | — | ◇ |
Rajiv Malik | ◇ | ◇ | — | — | — | ◇ | ◇ |
JoEllen Lyons Dillon | ◇ | ◇ | — | — | — | — | ◇ |
James M. Kilts | ◇ | ◇ | — | — | — | ◇ | ◇ |
Richard Mark | ◇ | ◇ | — | — | — | ◇ | ◇ |
Harry Korman | ◇ | ◇ | — | — | — | — | ◇ |
Leo Groothuis | ◇ | ◇ | — | — | — | — | ◇ |
W. Don Cornwell | ◇ | ◇ | — | — | — | ◇ | ◇ |
Elisha Finney | ◇ | ◇ | — | — | — | ◇ | ◇ |
Rogério Vivaldi Coelho | ◇ | ◇ | — | — | — | — | ◇ |
Frank D'Amelio | ◇ | ◇ | — | — | — | — | ◇ |
Michael Severino | ◇ | ◇ | — | — | — | — | ◇ |
David Simmons | ◇ | ◇ | — | — | — | — | ◇ |
Scott A. Smith served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Compensation committee chair | ◇ |
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x annual cash retainer ($750,000)
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Abbott Laboratories ABT
- Amgen Inc. AMGN
- Bausch Health Companies Inc. BHC
- Baxter International Inc. BAX
- Biogen Inc. BIIB
- Bristol-Myers Squibb Company BMY
- Gilead Sciences, Inc. GILD
- Novartis AG NVS
- Organon & Co. OGN
- Pfizer Inc. PFE
- Regeneron Pharmaceuticals, Inc. REGN
- Sandoz symbol not shown
- Sanofi S.A. SNY
- Teva Pharmaceutical Limited TEVA
- Zoetis Inc. ZTS
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 15, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | December 5, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | December 6, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | December 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | December 9, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | December 10, 2021 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Viatris disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Viatris sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
237 figures on this page: 231 cited to the filing that reported them, 6 calculated from figures it prints.
231 cited to the filing
6 calculated from the filing
Documents cited
- 0001140361-26-021672
- 0001140361-26-0130022025 Summary Compensation Table · CEO Pay Ratio · Grants of Plan-Based Awards · Non-Employee Director Compensation for 2025 · and 2 more sections
- 0001140361-25-044544
- 0001140361-25-0392632024 Summary Compensation Table
- 0001193125-24-272562
- 0001193125-24-2441732023 Summary Compensation Table
- 0001193125-23-296654
- 0001193125-22-301842
- 0001193125-21-359270
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Viatris executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/VTRS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Viatris and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Viatris discloses
The companies named in VTRS's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}